Showing 8741-8750 of 10121 results for "".
- Exosome News: ExoCoBio Completes Acquisition of Benevhttps://practicaldermatology.com/news/exosome-news-exocobio-completes-acquisition-of-benev/2461855/ExoCoBio has acquired a majority ownership in BENEV, a global medical aesthetic company that produces growth factor-based skincare products. ExoCoBio produces exosome-based regenerative aesthetics and medicine products and currently holds 54 patents and 15 scientific publicati
- RVL Launches New Prescription E-commerce Platformhttps://practicaldermatology.com/news/rvl-launches-new-prescription-e-commerce-platform/2461844/RVL Pharmaceuticals is launching a prescription e-commerce platform. ELEVATE is a secure subscription platform that allows both providers and patients to purchase RVL products. The platform comprises RVL-initiated auto refills and unlocks ad
- Dermatology Around the Globe: First JAK for AD Approved in Indiahttps://practicaldermatology.com/news/dermatology-around-the-globe-first-jak-for-ad-approved-in-india/2461828/Intas Pharmaceuticals Ltd launched TOFATAS –a Drugs Controller General of India (DCGI) -approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above experiencing flare-ups of the disease. "The
- Biosimilar News: Optum Rx Lists Cyltezo on Formularyhttps://practicaldermatology.com/news/biosimilar-news-optum-rx-lists-cyltezo-on-formulary/2461805/Optum Rx, a pharmacy benefit manager and subsidiary of UnitedHealth Group, will place Cyltezo (adalimumab-adbm) on its commercial formulary as a preferred brand, Boehringer Ingelheim reports. Cyltezo is a US Food and Drug Administration (FDA)-approved Interchangeable biosimilar to
- Deloitte Launches 'Illustrate Change' Medical Illustration Libraryhttps://practicaldermatology.com/news/deloitte-launches-illustrate-change-medical-illustration-library/2461794/Deloitte is launching "Illustrate Change," a project that seeks to increase representation in medical i
- Belotero Balance (+) Restores Volume to Under-eye Hollowshttps://practicaldermatology.com/news/belotero-balance-restores-volume-to-under-eye-hollows/2461782/Belotero Balance® (+) corrects volume loss in the infraorbital hollow area, according to new data from Merz Aesthetics. Merz Aesthetics will submit these data as part of a supplemental Premarket Approval Application (sPMA) with the U.S. Food and Drug Administration (FDA) this
- FDA Nod for Galderma's Restylane Eyelighthttps://practicaldermatology.com/news/fda-nod-for-galdermas-restylane-eyelight/2461760/The U.S. Food and Drug Administration (FDA) approved Restylane Eyelight, a hyaluronic acid (HA) dermal filler for the correction of undereye hollowing, in adults over the age of 21. Restylane Eyelight is formulated with NASHA Technology, which has a firm gel te
- EULAR News: Amgen's Otzela Cools Inflammation, May Improve CV Health in PsAhttps://practicaldermatology.com/news/eular-news-amgens-otzela-cools-inflammation-may-improve-cv-health-in-psa/2461749/Otezla (apremilast) showed promising results in cooling inflammation and reducing cardiometabolic risk factors in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), in Milan, Italy. The MOSAIC Phase
- Biosimilar Update: FDA Nod for High-Concentration, Citrate-Free Formulation of Humira Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-fda-nod-for-high-concentration-citrate-free-formulation-of-humira-biosimilar/2461740/The U.S. Food and Drug Administration (FDA) has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar. The FDA granted approval for the treatment of eight conditions: rheumatoid arthritis, juven
- LifeNet Health Acquires Bioventus's Wound Care Divisionhttps://practicaldermatology.com/news/lifenet-health-acquires-bioventuss-wound-care-division/2461711/LifeNet Health announced the expantion of its portfolio with the acquisition of Bioventus' wound care division. Financial terms of the acqusition were not disclosed. "Non-healing wounds are a modern health care crisis," LifeNet Health President an